This is the same PERCEPTIONS survey behind half would change jobs to get it covered — the same respondents (n = 518), a different set of questions [1]. Treating the two as independent evidence would be a mistake; treating this one as a picture of who arrives and why is not.
The stated motivations are less cosmetic than the public conversation about these drugs assumes. Improving overall health and wellbeing led at 83.8%, physical functioning came second at 58.3%, and confidence or appearance outside work third at 51.4%. Participants reported substantial impairment in physical functioning and psychosocial wellbeing at the point of starting, along with high internalized weight bias.
The barrier data is the part with commercial weight, and the ranking is instructive. Ninety percent named health insurance coverage as a barrier against 57.7% naming cost directly. That gap suggests what stops people is less the number on a price list than not knowing whether anyone else will pay it — which is consistent with the coverage confusion documented in covered and still not treated.
Two details describe the route people took. Nearly half had already tried and failed to lose weight or keep it off through diet and exercise, so this is largely not a first attempt. And 12.7% had previously taken semaglutide, meaning roughly one in eight arrived by switching rather than starting — a flow worth knowing when comparing products, as the super-responder brand comparison sets out.
One question the abstract leaves open should be named. It does not state funding, and it surveys people initiating one manufacturer’s drug — the same open question this desk raised about the companion paper. Nothing about the findings looks implausible, and a reader should know the provenance is unstated rather than assume it either way. What people report after longer on treatment, rather than at 26 days, is in what patients said when asked.